-
While combined oral contraceptives (OCs) remain a leading choice for contraception, other methods are making their mark. About 38% of respondents to the 2011 Contraceptive Technology Update Contraception Survey said more than half of their patients use OCs, a drop from 2010's 42% level.
-
New labeling is being eyed regarding increased risks for blood clots for the contraceptive patch and combined oral contraceptives (COCs) containing the progestin drospirenone (DRSP) following recommendations from joint votes from two Food and Drug Administration (FDA) committees.
-
Almost 75% of respondents to the Contraceptive Technology Update 2011 Contraception Survey say they provide advance provision of emergency contraception (EC).
-
To investigate whether gonadal hormones influence cognitive function in postmenopausal women, the authors administered a comprehensive battery of neuropsychological tests on two occasions (2 years apart) to participants enrolled in the population-based, longitudinal Melbourne Women's Midlife Health Project.
-
-
It might sound obvious to a reproductive medicine specialist to say that "every cell has a sex." On the other hand, even an obstetrician-gynecologist might be surprised to know how much of a contribution sex differences make to health and disease.
-
In this issue: New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
-
A number of previous reviews in OB/GYN Clinical Alert, including a Special Feature, have been devoted to preterm birth (PTB), a problem that has been on the rise in the United States despite significant efforts to curb it.
-
In this retrospective study of young women performed in New Zealand between 2005 and 2009, 57% of 452 patients with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 were treated immediately whereas 157 (35%) met the criteria for conservative management.
-
Women who carry a deleterious germline mutation in BRCA1 or BRCA2 have a substantially higher lifetime risk of developing ovarian cancer.
